Who is sponsoring HOVON 172 MF?

HOVON 172 MF is sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland.

What condition does HOVON 172 MF study?

HOVON 172 MF studies Myelofibrosis.

What is the status of HOVON 172 MF?

HOVON 172 MF is currently RECRUITING.

Last reviewed 2025-03-05 · How we verify

A Phase 1b/2 Trial with Tasquinimod in Patients with Myelofibrosis (primary, Post-PV or PostET) Refractory to or Intolerant for JAK2 Inhibition: the TasqForce Trial (HOVON 172 MF)

NCT06605586 Phase 1/Phase 2 RECRUITING

The goal of this clinical trial is to learn if therapy can be improved in patients with myelofibrosis (MF) who have primary resistance or who have progressed after treatment with a Janus kinase (JAK) inhibitor or are intolerant for this category of drugs. The main questions it aims to answer are: * To evaluate the feasibility and safety of once daily dose of tasquinimod for 24 weeks (6 cycles) * To determine the optimal dose Patients will be treated once daily with tasquinimod for a maximum period of 24 weeks (6 cycles). During the study most (diagnostic) procedures are part of the standard of care. Different from standard of care: * Participation may lead to extra visits to the outpatient clinic * Additional blood will be drawn when blood is already taken per standard of care * Bone marrow sampling at entry and at the end of the trial * MRI scans (or CT-scans) have to be performed * Quality-of-life questionnaires have to be filled out

Details

Lead sponsor	Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase	Phase 1/Phase 2
Status	RECRUITING
Enrolment	20
Start date	2025-02-20
Completion	2030-03

Conditions

Myelofibrosis

Interventions

Tasquinimod

Primary outcomes

SVR35W24 — 24 weeks after start treatment
Proportion of patients with at least 35% reduction in spleen volume from baseline at Week 24 (SVR35W24) as measured by magnetic resonance imaging (MRI) or computed tomography (CT) scan, per International Working Group (IWG) criteria, based on MRI review.
DLT phase I — From enrollment until 28 days after start treatment
To determine the dose limiting toxicity (DLT) of tasquinimod. Pre-defined adverse events (AEs) that occur within 28 days of the start of study treatment will be considered a DLT, unless the AE is definitely unrelated to tasquinimod.

Countries

Germany, Netherlands